The short version
Just 3 companies supply this market — thin enough that a single exit would be felt immediately.
The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.
Eptifibatide
eptifibatide · EPTIFIBATIDE .75 mg/mL · Injection · Intravenous · Slate Run Pharmaceuticals, LLC
NDC 70436-0027-80 · 100 mL in 1 VIAL · ANDA · View full market →
Medicare Part D
No Medicare Part D plan in CMS's quarterly files lists this product. That usually means it is discontinued, a repackager's listing, or a product no plan has added to its formulary.
How Part D pricing works →NADAC price per unit
No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.
Estimated fill cost
WAC per package, as filed
$20.00
Reported to Texas DSHS · 2025 annual filing · Slate Run Pharmaceuticals, LLC.
Manufacturer list price as filed — not what pharmacies actually pay after discounts.
Supply fragility
Not scored — fragility is computed for NADAC-priced NDCs.
Where it's made
- analysis · manufacture · pack
Establishments this product's FDA label declares, located via FDA registration data. How we built this →
Is this a "specialty" drug?
There's no legal definition — it meets 1 of 6 public criteria. Why that matters →
- Part D specialty tier
- Costs ≥ $950/fill
- Biologic (BLA)
- Injectable / infused
- Orphan-drug exclusivity
- REMS program
Regulatory
- Application
- ANDA209864
- TE code
- AP
- Approval date
- Jan 25, 2019
- Patents / exclusivity
- None on file
Shortage history
No FDA shortage reports for this drug or its presentations.
Recalls (this NDC)
- Class III · OngoingFeb 12, 2026Slate Run Pharmaceuticals — Labeling: Not Elsewhere Classified. The carton for Eptifibatide Injection 75 mg/100 mL states 75 mg/100 mL vial for weight-adjusted bolus dosing. The approved statement is 75 mg/100 mL vial for weight-adjusted infusion.
Manufacturers of eptifibatide (Injection)
| Labeler | Strength | First seen | Last seen |
|---|---|---|---|
| Slate Run Pharmaceuticals, LLC | EPTIFIBATIDE .75 mg/mL | Jul 15, 2026 | Sep 3, 2026 |
| Baxter Healthcare Company | EPTIFIBATIDE 75 mg/100mL | Jul 15, 2026 | Sep 2, 2026 |
| Eugia US LLC | EPTIFIBATIDE 20 mg/10mL | Jul 15, 2026 | Sep 2, 2026 |
| Eugia US LLC | EPTIFIBATIDE 200 mg/100mL | Jul 15, 2026 | Sep 2, 2026 |
| Eugia US LLC | EPTIFIBATIDE 75 mg/100mL | Jul 15, 2026 | Sep 2, 2026 |
| Slate Run Pharmaceuticals, LLC | EPTIFIBATIDE 2 mg/mL | Jul 15, 2026 | Aug 31, 2026 |
Roster from daily NDC Directory diffs — first/last seen dates start July 2026.
Cite this page
DrugDashboards, "Eptifibatide — NDC 70436-0027-80," retrieved September 3, 2026, https://drugdashboards.com/drug/70436002780.
Free to cite with attribution — see how the data is put together.